Related Experiment Videos
Cis-dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas
Cancer Treatment Reports
|November 1, 1979
Summary
cis-Dichlorodiammineplatinum(II) demonstrated efficacy in patients with metastatic sarcomas. This platinum-based chemotherapy showed promising results, including complete regressions and disease stabilization, with good tolerability.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic sarcomas are challenging to treat, often requiring salvage chemotherapy after initial treatment failure.
- Platinum-based agents are a cornerstone in various cancer therapies.
Purpose of the Study:
- To evaluate the efficacy and toxicity of cis-Dichlorodiammineplatinum(II) as a single agent in patients with advanced sarcomas.
- To assess response rates and duration in a heavily pre-treated patient population.
Main Methods:
- A cohort of 13 patients with metastatic sarcomas, who had progressed on two prior chemotherapy regimens, received cis-Dichlorodiammineplatinum(II).
- Tumor response was assessed, and toxicity was monitored.
Main Results:
- Two patients achieved complete regression, with one lasting 8 months and the other 6 months.
- One patient experienced over 50% regression lasting 5 months.
- Three patients achieved disease stabilization for 2 months each.
- cis-Dichlorodiammineplatinum(II) was well-tolerated, with no significant renal or auditory toxicity observed.
Conclusions:
- cis-Dichlorodiammineplatinum(II) shows significant activity in metastatic sarcomas refractory to standard chemotherapy.
- The agent is well-tolerated, suggesting a favorable risk-benefit profile for this patient group.